Pharyngitis streptococcal adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 10,665 adverse event reports that record the MedDRA preferred term Pharyngitis streptococcal. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 527 reports in the 12 months to June 2026 and 751 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 956 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 527 (under 0.1%) record this term. Reports for female patients were 69.1% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 150 drug pages with 10 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Pharyngitis streptococcal name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		24
Actemra	Interleukin-6 receptor antagonist	98
Adalimumab	Tumor necrosis factor blocker	16
Advair Diskus	Corticosteroid	13
Advate		18
Afinitor	Kinase inhibitor	28
Agamree		18
Alemtuzumab	CD52-directed cytolytic antibody	14
Alli	Intestinal lipase inhibitor	12
Ambrisentan	Endothelin receptor antagonist	37
Amoxicillin	Penicillin-class antibacterial	73
Ampyra	Potassium channel blocker	12
Aubagio	Pyrimidine synthesis inhibitor	17
Avonex	Interferon beta	65
Azithromycin Anhydrous		10
Benlysta	B lymphocyte stimulator-specific inhibitor	28
Bimekizumab		12
Bimzelx		33
Budesonide	Corticosteroid	12
Certolizumab pegol	Tumor necrosis factor blocker	75
Certolizumab Pegol Ra		11
Cimzia	Tumor necrosis factor blocker	154
Ciprofloxacin	Fluoroquinolone antibacterial	15
Codeine		15
Colchicine	Alkaloid	20
Copaxone		11
Corticotropin		10
Cosentyx	Interleukin-17A antagonist	442
Covid-19 Vaccine		12
Crysvita		27
Cuvitru	Human immunoglobulin G	21
Cyclophosphamide	Alkylating drug	12
Cymbalta		25
Daybue		65
Dexamethasone	Corticosteroid	10
Dupixent	Interleukin-4 receptor alpha antagonist	614
Eliquis	Factor Xa inhibitor	29
Emflaza	Corticosteroid	11
Enbrel	Tumor necrosis factor blocker	1,142
Entresto	Angiotensin 2 receptor blocker	22
Entyvio	Integrin receptor antagonist	38
Epidiolex		11
Fabrazyme	Hydrolytic lysosomal neutral glycosphingolipid-specific enzyme	17
Fintepla		19
Forteo	Parathyroid hormone analog	21
Fosamax	Bisphosphonate	16
GAMMAGARD Liquid	Human immunoglobulin G	22
Genotropin		18
Gilenya	Sphingosine 1-phosphate receptor modulator	66
Hemlibra		18
Hizentra	Human immunoglobulin G	51
Humalog	Insulin analog	10
Human immunoglobulin g	Human immunoglobulin G	162
Human Immunoglobulin G Hyaluronidase Recombinant Human		23
Humira		1,278
Humira 40 Mg/0 8 Ml Pen		72
Humira 40 Mg/0 8 Ml Pre-Filled Syringe		20
Hydrocortisone	Corticosteroid	16
Ibrance	Kinase inhibitor	28
Ibuprofen	Nonsteroidal anti-inflammatory drug	20
Ilaris		51
Imbruvica	Kinase inhibitor	23
Imodium	Opioid agonist	22
Inflectra	Tumor necrosis factor blocker	214
Infliximab	Tumor necrosis factor blocker	129
Ipratropium bromide	Anticholinergic	11
Kalydeco	Cystic fibrosis transmembrane conductance regulator potentiator	18
Kesimpta	CD20-directed cytolytic antibody	35
Kevzara	Interleukin-6 receptor antagonist	24
Kineret	Interleukin-1 receptor antagonist	24
Kuvan		19
Lamictal	Anti-epileptic agent	16
Lanadelumab		10
Leflunomide	Antirheumatic agent	43
Letairis	Endothelin receptor antagonist	29
Lyrica		22
Methotrexate	Folate analog metabolic inhibitor	172
Methotrexate sodium	Folate analog metabolic inhibitor	36
Metoprolol tartrate	beta-Adrenergic blocker	11
Mirena	Progestin	27
Mounjaro	GLP-1 receptor agonist	20
Mycophenolate mofetil	Antimetabolite immunosuppressant	20
Nexium	Proton pump inhibitor	26
Nutropin Aq		10
Nuvaring	Estrogen	22
Ocrevus	CD20-directed cytolytic antibody	79
Olumiant	Janus kinase inhibitor	10
Omalizumab	Anti-IgE	36
Ondansetron	Serotonin-3 receptor antagonist	15
Opsumit	Endothelin receptor antagonist	33
Orencia	Selective T cell costimulation modulator	45
Orenitram	Prostacycline vasodilator	10
Orkambi	Cystic fibrosis transmembrane conductance regulator potentiator	27
Ortho Evra		13
Otezla	Phosphodiesterase 4 inhibitor	87
Oxbryta		10
Oxycodone	Opioid agonist	10
Oxycodone hydrochloride	Opioid agonist	20
Ozempic	GLP-1 receptor agonist	13
Palforzia		14
Pantoprazole sodium	Proton pump inhibitor	16
Pegasys	Interferon alpha	14
Penicillin		13
Plan B One-Step	Progestin	22
Plaquenil	Antimalarial	13
Pomalyst	Thalidomide analog	37
Prednisone	Corticosteroid	70
Pregabalin		21
Rebif	Interferon beta	46
Remicade	Tumor necrosis factor blocker	260
Remodulin	Prostacycline vasodilator	25
Repatha	PCSK9 inhibitor	33
Revatio	Phosphodiesterase 5 inhibitor	10
Revlimid	Thalidomide analog	88
Rinvoq	Janus kinase inhibitor	119
Rituxan	CD20-directed cytolytic antibody	18
Rituximab	CD20-directed cytolytic antibody	35
Sandostatin	Somatostatin analog	13
Sandostatin LAR Depot		16
Seroquel	Atypical antipsychotic	13
Simponi	Tumor necrosis factor blocker	61
Skyrizi	Interleukin-23 antagonist	108
Soliris	Complement inhibitor	43
Stelara	Interleukin-12 antagonist	64
Strattera	Norepinephrine reuptake inhibitor	25
Strensiq		28
Symbicort	Corticosteroid	20
Taltz	Interleukin-17A antagonist	116
Tarpeyo	Corticosteroid	10
Tecfidera		67
Teduglutide	GLP-2 analog	20
Tiotropium bromide	Anticholinergic	19
Tracleer	Endothelin receptor antagonist	15
Tremfya	Interleukin-23 antagonist	19
Trikafta		11
Tysabri	Integrin receptor antagonist	304
Tyvaso	Prostacycline vasodilator	29
Vedolizumab	Integrin receptor antagonist	137
Veletri	Prostacycline vasodilator	12
Vimizim	Hydrolytic lysosomal glycosaminoglycan-specific enzyme	23
Vioxx		12
Xeljanz	Janus kinase inhibitor	220
Xolair	Anti-IgE	83
Xyrem	Central nervous system depressant	80
Xywav	Central nervous system depressant	17
Yaz		13
Zithromax	Macrolide antimicrobial	10
Zofran		40
Zofran Odt		28
Zoloft	Serotonin reuptake inhibitor	14

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 43 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Pharyngitis streptococcal name, in order of name
Class	Reports with this term
Angiotensin 2 receptor blocker	32
Anti-epileptic agent	29
Anti-IgE	119
Anticholinergic	44
Antirheumatic agent	43
Atypical antipsychotic	31
B lymphocyte stimulator-specific inhibitor	30
beta-Adrenergic blocker	28
CD20-directed cytolytic antibody	174
Central nervous system depressant	104
Complement inhibitor	47
Corticosteroid	212
Cystic fibrosis transmembrane conductance regulator potentiator	45
Endothelin receptor antagonist	120
Estrogen	27
Factor Xa inhibitor	36
Folate analog metabolic inhibitor	212
GLP-1 receptor agonist	60
Human immunoglobulin G	261
Hydrolytic lysosomal glycosaminoglycan-specific enzyme	46
Integrin receptor antagonist	479
Interferon beta	117
Interleukin-1 receptor antagonist	27
Interleukin-12 antagonist	64
Interleukin-17A antagonist	560
Interleukin-23 antagonist	129
Interleukin-4 receptor alpha antagonist	623
Interleukin-6 receptor antagonist	130
Janus kinase inhibitor	370
Kinase inhibitor	116
Nonsteroidal anti-inflammatory drug	44
Norepinephrine reuptake inhibitor	25
Opioid agonist	114
PCSK9 inhibitor	37
Penicillin-class antibacterial	82
Phosphodiesterase 4 inhibitor	90
Progestin	53
Prostacycline vasodilator	86
Proton pump inhibitor	51
Selective T cell costimulation modulator	51
Sphingosine 1-phosphate receptor modulator	66
Thalidomide analog	141
Tumor necrosis factor blocker	2,075

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Pharyngitis streptococcal, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Pharyngitis streptococcal
Age	Reports	Share
Under 2	32	0.3%
2 to 11	742	7%
12 to 17	423	4%
18 to 44	2,917	27.4%
45 to 64	2,135	20%
65 to 74	582	5.5%
75 and over	184	1.7%
Age not given	3,650	34.2%

Sex of the patient in the reports that record Pharyngitis streptococcal
Sex	Reports	Share
Female	7,370	69.1%
Male	2,525	23.7%
Unknown or not given	770	7.2%

Age and sex are as the report gives them. 83.6% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Pharyngitis streptococcal: adverse event reports that record this term. https://reportedreactions.com/reaction/pharyngitis-streptococcal/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Pharyngitis streptococcal mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page